From the Journals

2024–2025 Drug Updates in Solid Tumors

Share

  • 1

    Dr. Chen presented updates on treatments for solid tumors.

  • 2

    NRG1 fusion-positive tumors can be treated with Zenocutuzumab.

  • 3

    Avutometinib is designed for low-grade serous ovarian cancer.

  • 4

    Stomatitis is a common side effect of Datopotamab deruxtecan.

  • 5

    Dordaviprone is approved for H3 K27M-mutant diffuse midline glioma.

  • 6

    Understanding mechanisms of action is vital for managing treatment toxicities.

  • 7

    Quality of life is a priority in cancer treatment planning.

Original Source(s)

2024–2025 Drug Updates in Solid Tumors

  • by Kevin Y. Chen, PharmD, MS, BCOP, CPP

  • February 27, 2026

  • 13 min

Related Content

The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

  • February 24, 2026

  • 2 min
Baptist Health Miami Cancer Institute Names Bruna Pellini, M.D., Chief of Thoracic Medical Oncology

Board-certified thoracic oncologist Bruna Pellini, M.D., has been named chief of thoracic medical oncology at Baptist Health Miami Cancer Institute.

  • by

  • February 6, 2026

  • 3 min
The Role of Human Leukocyte Antigens in Reducing Lung Cancer Risk

With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's protective function against cancer.

  • by

  • February 5, 2025

  • 1 min